Dakota Wealth Management Sells 1,053 Shares of Becton, Dickinson and Company (NYSE:BDX)

Dakota Wealth Management lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 4.0% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,104 shares of the medical instruments supplier’s stock after selling 1,053 shares during the quarter. Dakota Wealth Management’s holdings in Becton, Dickinson and Company were worth $6,053,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. WR Wealth Planners LLC raised its stake in shares of Becton, Dickinson and Company by 1.4% during the 2nd quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 42 shares during the period. Clear Creek Financial Management LLC raised its position in Becton, Dickinson and Company by 5.1% during the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its holdings in Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Central Pacific Bank Trust Division grew its position in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC increased its stake in shares of Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock worth $326,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2 %

Shares of NYSE:BDX opened at $238.13 on Friday. The company has a market capitalization of $68.82 billion, a price-to-earnings ratio of 52.45, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The business has a 50-day moving average price of $237.43 and a 200 day moving average price of $235.18. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. During the same period in the previous year, the firm earned $2.96 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Sell-side analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BDX. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their target price for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Evercore ISI boosted their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.